PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 69-76

  Baron, Morgane ^a,b,c   Leroyer, Aurélie S ^d   Majd, Zouher ^d   Lalloyer, Fanny ^a,b,c   Vallez, Emmanuelle ^a,b,c   Bantubungi, Kadiombo ^a,b,c   Chinetti Gbaguidi, Giulia ^a,b,c   Delerive, Philippe ^e   Boulanger, Chantal M ^d   Staels, Bart ^a,b,c   Tailleux, Anne ^a,b,c  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^e Genfit SA   (France)

Author keywords

Atherosclerosis; Fatty liver disease; Microparticles; Murine model; Pharmacology

Indexed keywords

BIOLOGICAL MARKER; CELL NUCLEUS RECEPTOR; FENOFIBRATE; GELATINASE B; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; LIVER; MEMBRANE VESICLE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; TISSUE SPECIFICITY;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL-DERIVED MICROPARTICLES; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; FENOFIBRATE; FLOW CYTOMETRY; HUMANS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PPAR ALPHA;

EID: 80052270962     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.009     Document Type: Article

References (41)

1. Bayturan O., Tuzcu E.M., Lavoie A., et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010, 170:478-484.
2. Parekh S., Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007, 132:2191-2207.
3. Ludwig J., McGill D.B., Lindor K.D. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997, 12:398-403.
4. Lusis A.J., Atherosclerosis Nature 2000, 407:233-241.
5. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
6. Herman M.P., Sukhova G.K., Kisiel W., et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001, 107:1117-1126.
7. Menghini R., Menini S., Amoruso R., et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 2009, 136:663-672.
8. Serino M., Menghini R., Fiorentino L., et al. Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007, 56:2541-2546.
9. Piccin A., Murphy W.G., Smith O.P. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007, 21:157-171.
10. Goichot B., Grunebaum L., Desprez D., et al. Circulating procoagulant microparticles in obesity. Diabetes Metab 2006, 32:82-85.
11. Heiss C., Amabile N., Lee A.C., et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. J Am Coll Cardiol 2008, 51:1760-1771.
12. Nomura S., Kanazawa S., Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002, 16:539-547.
13. Sabatier F., Darmon P., Hugel B., et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002, 51:2840-2845.
14. Bernard S., Loffroy R., Sérusclat A., et al. Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis 2009, 203:429-435.
15. Bernal-Mizrachi L., Jy W., Jimenez J.J., et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003, 145:962-970.
16. Leroyer A.S., Isobe H., Lesèche G., et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007, 49:772-777.
17. Kornek M., Popov Y., Libermann T.A., Afdhal N.H., Schuppan D. Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology 2011, 53:230-242.
18. Brodsky S.V., Facciuto M.E., Heydt D., et al. Dynamics of circulating microparticles in liver transplant patients. J Gastrointestin Liver Dis 2008, 17:261-268.
19. Sturk-Maquelin K.N., Nieuwland R., Romijn F., Eijsman L., Hack C.E., Sturk A. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003, 1:1920-1926.
20. Mesri M., Altieri D.C. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999, 274:23111-23118.
21. Leroyer A.S., Rautou P., Silvestre J., et al. CD40 ligand+microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol 2008, 52:1302-1311.
22. Agouni A., Lagrue-Lak-Hal A.H., Ducluzeau P.H., et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008, 173:1210-1219.
23. Esposito K., Ciotola M., Giugliano D. Pioglitazone reduces endothelial microparticles in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:1926.
24. Nomura S., Shouzu A., Omoto S., Nishikawa M., Iwasaka T. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost 2004, 10:133-141.
25. Lefebvre P., Chinetti G., Fruchart J., Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006, 116:571-580.
26. Hennuyer N., Tailleux A., Torpier G., et al. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2005, 25:1897-1902.
27. Srivastava R., Jahagirdar R., Azhar S., Sharma S., Bisgaier C.L. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem 2006, 285:35-50.
28. Duez H., Chao Y., Hernandez M., et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 2002, 277:48051-48057.
29. Staels B., Maes M., Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008, 5:542-553.
30. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
31. Shiri-Sverdlov R., Wouters K., Van Gorp P.J., et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 2006, 44:732-741.
32. Sullivan P.M., Mezdour H., Quarfordt S.H., Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest 1998, 102:130-135.
33. Lee S.S., Pineau T., Drago J., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995, 15:3012-3022.
34. Amabile N., Guérin A.P., Leroyer A., et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005, 16:3381-3388.
35. Woollard K.J., Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010, 7:77-86.
36. Ghosh A., Li W., Febbraio M., et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008, 118:1934-1943.
37. Ravichandran K.S., Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 2007, 7:964-974.
38. Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. Antioxid Redox Signal 2009, 11:2333-2339.
39. Ait-Oufella H., Kinugawa K., Zoll J., et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 2007, 115:2168-2177.
40. Li A.C., Binder C.J., Gutierrez A., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004, 114:1564-1576.
41. Day C.P., James O.F. Steatohepatitis: a tale of two hits?. Gastroenterology 1998, 114:842-845.